228 related articles for article (PubMed ID: 30941437)
1. [Treatment of multiple myeloma with elotuzumab plus pomalidomide and dexamethasone].
Rasche L; Einsele H; Nitschmann S
Internist (Berl); 2019 Jun; 60(6):658-660. PubMed ID: 30941437
[No Abstract] [Full Text] [Related]
2. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
Dimopoulos MA; Dytfeld D; Grosicki S; Moreau P; Takezako N; Hori M; Leleu X; LeBlanc R; Suzuki K; Raab MS; Richardson PG; Popa McKiver M; Jou YM; Shelat SG; Robbins M; Rafferty B; San-Miguel J
N Engl J Med; 2018 Nov; 379(19):1811-1822. PubMed ID: 30403938
[TBL] [Abstract][Full Text] [Related]
3. Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma.
Hulin C; Beksac M; Goodman HJ; Spicka I; Alegre A; Prince M; Campana F; Finn G; Le-Guennec S; Macé S; Muccio S; Tavernier A; Rouchon MC; Richardson PG
Blood Cancer J; 2021 Oct; 11(10):169. PubMed ID: 34671024
[No Abstract] [Full Text] [Related]
4. Elotuzumab in multiple myeloma.
Burki TK
Lancet Oncol; 2018 Dec; 19(12):e675. PubMed ID: 30449660
[No Abstract] [Full Text] [Related]
5. Pomalidomide in heavily pretreated refractory multiple myeloma: a case report.
Palmas A; Piras G; Uras A; Asproni R; Murineddu M; Monne M; Stradoni R; Latte G
Future Oncol; 2017 Feb; 13(5s):7-9. PubMed ID: 28116939
[TBL] [Abstract][Full Text] [Related]
6. Second elotuzumab triplet efficacious in MM.
Killock D
Nat Rev Clin Oncol; 2019 Feb; 16(2):67. PubMed ID: 30478425
[No Abstract] [Full Text] [Related]
7. Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma.
Eleutherakis-Papaiakovou E; Gavriatopoulou M; Ntanasis-Stathopoulos I; Kastritis E; Terpos E; Dimopoulos MA
Expert Rev Anticancer Ther; 2019 Nov; 19(11):921-928. PubMed ID: 31679403
[No Abstract] [Full Text] [Related]
8. Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma.
Conticello C; Parisi M; Romano A; Calafiore V; Ancora F; La Fauci A; Consoli ML; Di Raimondo F
Future Oncol; 2017 Feb; 13(5s):3-6. PubMed ID: 28116941
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
Afifi S; Michael A; Lesokhin A
Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
[TBL] [Abstract][Full Text] [Related]
10. Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211.
Usmani SZ; Sexton R; Ailawadhi S; Shah JJ; Valent J; Rosenzweig M; Lipe B; Zonder JA; Fredette S; Durie B; Hoering A; Bartlett B; Orlowski RZ
Blood Cancer J; 2015 Aug; 5(8):e334. PubMed ID: 26252787
[No Abstract] [Full Text] [Related]
11. Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy.
Ríos-Tamayo R; Martín-García A; Alarcón-Payer C; Sánchez-Rodríguez D; de la Guardia AMDVD; García Collado CG; Jiménez Morales A; Jurado Chacón M; Cabeza Barrera J
Drug Des Devel Ther; 2017; 11():2399-2408. PubMed ID: 28860711
[TBL] [Abstract][Full Text] [Related]
12. Toxic epidermal necrolysis following thalidomide and dexamethasone treatment for multiple myeloma: a case report.
Eo WK; Kim SH; Cheon SH; Lee SH; Jeong JS; Kim YS; Chang HK; Suh KS; Kim HY
Ann Hematol; 2010 Apr; 89(4):421-2. PubMed ID: 19693501
[No Abstract] [Full Text] [Related]
13. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.
Bringhen S; Pour L; Vorobyev V; Vural F; Warzocha K; Benboubker L; Koh Y; Maisnar V; Karlin L; Pavic M; Campana F; Le Guennec S; Menas F; van de Velde H; Richardson PG
Leuk Res; 2021 May; 104():106576. PubMed ID: 33839618
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma.
Ide T; Osawa M; Sanghavi K; Vezina HE
Cancer Chemother Pharmacol; 2022 Jan; 89(1):129-140. PubMed ID: 34825942
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide plus dexamethasone in multiple myeloma.
Das M
Lancet Oncol; 2018 Jan; 19(1):e12. PubMed ID: 29175148
[No Abstract] [Full Text] [Related]
16. Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma.
Laubach JP; Paba Prada CE; Richardson PG; Longo DL
Clin Pharmacol Ther; 2017 Jan; 101(1):81-88. PubMed ID: 27806428
[TBL] [Abstract][Full Text] [Related]
17. Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study.
Regidor B; Swift R; Eades B; Emamy-Sadr M; Tarhini F; Spektor TM; Berenson JR
Ann Hematol; 2021 Apr; 100(4):1079-1085. PubMed ID: 33237342
[TBL] [Abstract][Full Text] [Related]
18. New immunomodulatory drugs in myeloma.
Lacy MQ
Curr Hematol Malig Rep; 2011 Jun; 6(2):120-5. PubMed ID: 21327565
[TBL] [Abstract][Full Text] [Related]
19. A Clinician's Perspective of Elotuzumab in the Treatment of Relapsed or Refractory Multiple Myeloma.
Richardson PG
Clin Adv Hematol Oncol; 2019 May; 17 Suppl 9(5):2-8. PubMed ID: 32720924
[No Abstract] [Full Text] [Related]
20. A Clinician's Perspective of Elotuzumab in the Treatment of Relapsed or Refractory Multiple Myeloma.
Clin Adv Hematol Oncol; 2019 May; 17 Suppl 9(5):1-19. PubMed ID: 32720923
[No Abstract] [Full Text] [Related]
[Next] [New Search]
